1Thompson GR,Hollyer J,Waters DD.Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease.Curr Opin Lipidol,1995,6:386-388.
2Jukema JW, Bruschke AVG, Boven AJ,et al.Effects of lipid lowering by provastatin on progression and regression of coronary heart disease in symptomatic men with normal to moderately elevated serum cholesterol levels:the Regression Growth Evaluation Statin Study(REGRESS).Circulation, 1995,91:2528-2540.
3Moreno PR, Falk E, Palacios IF,et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation, 1994,90:775-778.
4Idrissia A,Nicolas D,Claudio I,et al.C-Reactive protein and coronary artery disease: Additional evidence of the implication of an inflammatory process in acute coronary syndromes.Am Heart J, 1999,137:346-351.
5Lindahl B,Toss H,Siegbahn A,et al.Markers of myocardiol damage and inflammation inrelation to long term mortality in unstable coronary artery disease.FRISC study group.fragmin during instability in coronary artery disease. N Engl J Med,2000,343:1139.
6Winter RJ.Independent Prognostic Value of C-reactive protein and troponin Iin patients with unstable angina of non-Q-wave myocardial Infarction.Cardiovasc Res, 1999,42:240-245.
7Biasucci LM,Liuzzo G,Grillo RL,et al.Elevated levels of C-reactiva protein at discharge in patients with unstable angina predict recurrent instability.Circulation, 1999,99:855-860.
8Ferreiros ER,Boissonnet CP,Pizarro R,et al.Independent prognostic value of elevated C-reactive protein in unstable angina.Circulation, 1999,100:1958-1963.
9Becker RC,Cannon CP, Bovil EG,et al.Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q wave myocardial infarction.Am J Cardiol, 1996,78:142-147.
10Libby P,Ridker PM, Maseri Attilio.Inflammation and atherosclerosis.Circulation, 2002,105:1135-1143.
3Cannon CP,Steinberg BA,Mushy SA,et al.Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.J Am Coll Cardiol,2006,48:438-445.
4Expert panel on detection,evaluationg,and treatment of high blood cholesterol in adults.Executive summary of the third report of thenational cholesterol education program(NCEP)expert panel on detection,evaluationg,and treatment of high blood cholesterol in adults(Adult treatment panel Ⅲ).JAMA,2001,285:2486-2497.
5Grundy SM,Cleeman JI,Merz CN,et al.Implications of rccent clinical trials for the national cholesterol education program adult treatment panel Ⅲ guidelines.Circulation,2004,110:227-239.
6Serruys PW,De Feyter PJ,Benghozi R,et al.The Lescol(R)intervention prevention study(UPS):a double-blind,placebo-controlled,randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease.Int J Cardiovasc Intervent,2001,4:165-172.
7Davignon J.Beneficial cardiovascular phiotropic effects of st-atins.Circulation,2004,109:Ⅲ,39-43.
8Williams JK,Sukhova GK,Herrington DM,et al.Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.J Am Coll Cardiol.1998:684-691.
9Stefanadis C,Toutouzas K,Vavuranakis M,et al.Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques.Eur Heart J,2002:1664-1669.
10Puccetti L,Bruni F,Bova G,et al.Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolcmic subjects.Nutr Metab Cardiovase Dis,2001,11:378-387.
